Interim Chief Scientific Officer · Voyager Therapeutics, Inc. (VYGR)

Glenn Pierce

FY2021 is the first fiscal year CompBrief holds for Glenn Pierce as a named executive officer of Voyager Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$552,679

Salary $293,272Stock awards $0

6th of 6 named executive officers at Voyager Therapeutics by FY2021 total.

6 named officers on file for Voyager Therapeutics, FY2021

Glenn Pierce’s pay file — $29

  • 1 fiscal year of pay, line by line
  • VYGR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Voyager Therapeutics’s whole pay program stands against its peers

  • Voyager Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VYGR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Glenn Pierce’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Glenn Pierce compensation by year

Voyager Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Voyager Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$293,272
Bonus$0
Stock awards$0
Option awards$259,407
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$552,679

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Voyager Therapeutics, Inc. DEF 14A filed April 21, 2022, accession 0001558370-22-005685, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Voyager Therapeutics, Inc. filed document, accession 0001558370-22-005685. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option25,004—$4.23
Option21,000—$4.45

Per the Outstanding Equity Awards at Fiscal Year-End table in Voyager Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2021 proxy (filed April 21, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-09Grant or award derivative—30,000$0.0030,000
2025-06-03Grant or award derivative—24,000$0.0024,000

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Voyager Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
G. Andre TurenneFormer President and Chief Executive Officer$2,630,096
Robert HessleinSenior Vice President and General Counsel$1,314,955
Allison DorvalFormer Chief Financial Officer$1,131,523
Omar KhwajaFormer Chief Medical Officer and Head of Research and Development$996,529
Michael HigginsFormer Interim President and Chief Executive Officer$696,063
Glenn Pierce · this pageInterim Chief Scientific Officer$552,679

Board service

Voyager Therapeutics board · FY2021–FY2025
Director compensation in US dollars, as Voyager Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$51,000$0$53,760$0$104,760
FY2024$51,000—$144,000$0$195,000
FY2023$51,000—$197,780$0$248,780
FY2021$21,888—$259,407$0$281,295

Each year as the company reported it in Voyager Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Voyager Therapeutics pays directors a $40,000 cash retainer. As stated in Voyager Therapeutics's FY2025 proxy.

Committees

Compensation · Science and Technology

The full Voyager Therapeutics compensation record

free company brief

This page is one person within Voyager Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Voyager Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Voyager Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Glenn Pierce's compensation dossier · One-time report. No refunds.